relatlimab (BMS-986016) - BMS
Opdivo (nivolumab) - Ono Pharmaceutical, BMS
Plain language summary of the RELATIVITY-098 study results: nivolumab plus relatlimab given after melanoma is removed by surgery. (PubMed, Future Oncol) - Sep 23, 2026 - No abstract available 
Journal • Melanoma • Oncology • Solid Tumor
http://www.ncbi.nlm.nih.gov/pubmed/42770835
 
Ahmad A Tarhini; Alicia M Y Cheong; Andréia Cristina de Melo; Andrew Fisher; Armand Chouzy; Bohang Chen; Bonnie Wang; Charlie Garnett-Benson; Dirk Schadendorf; Eva Muñoz-Couselo; Gaelle Quereux; Georgina V Long; Helen Gogas; Hussein A Tawbi; Ioannis Thomas; Jia Xin Yu; Jun Guo; Margaret Callahan; Mark Semaan; Michele Del Vecchio; Paolo A Ascierto; Patrick Djidel; Peter Koelblinger; Reinhard Dummer; Sonia Dolfi; Sunandana Chandra
 
Sep 23, 2026
 
Prev Next